Europe buys Gilead’s remdesivir for 500,000 Covid-19 patients amid supply worries

Gilead Sciences said on Thursday it had agreed to sell Europe up to 500,000 courses of its antiviral drug remdesivir, as the continent scrambles to shore up supplies of one of only two drugs approved to treat Covid-19 patients.

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *